Ares Trading S.A.
Records under this name other than the patents Ares Trading S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 61 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,852,591 | Combination of Blys And/Or April Inhibition and Immunosuppressants for Treatment of Autoimmune Disease Formerly held In force · High confidence | In force | High confidence | |
| US 8,956,611 | COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE Formerly held In force · High confidence | In force | High confidence | |
| US 9,279,014 | Methods for preparing an active TNFR-Fc fusion protein Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,504,679 | Pharmaceutical compositions comprising glitazones and Nrf2 activators Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,426,763 | Pharmaceutical compositions comprising glitazones and NRF2 activators Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,484,530 | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,083,107 | Pharmaceutical compositions comprising glitazones and Nrf2 activators Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,221,456 | Genetic Markers for Predicting Responsiveness to FGF-18 Compound Formerly held In force · High confidence | In force | High confidence | |
| US 10,426,832 | Liquid pharmaceutical composition Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,426,833 | Liquid pharmaceutical composition Formerly held In force · From the USPTO record | In force | From the USPTO record |